Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Jul;115(5):795–800. doi: 10.1111/j.1476-5381.1995.tb15003.x

Mechanisms of angiotensin II chronotropic effect in anaesthetized dogs.

C Lambert 1
PMCID: PMC1908529  PMID: 8548179

Abstract

1. The chronotropic effect of angiotensin II (5 micrograms in 1 ml of Tyrode solution), injected directly into the sinus node artery of 24 anaesthestized and vagotomized dogs pretreated with a beta-adrenoceptor antagonist, was evaluated before and after the administration of: (a) an angiotensin II AT1 receptor antagonist (losartan, 50 micrograms kg-1 min-1 infused i.v. for 120 min), (b) an alpha-adrenoceptor antagonist (prazosin, 1 mg kg-1 i.v. bolus injected), (c) a Ca2+ channel blocker (nifedipine 50, 100 and 200 micrograms kg-1 i.v. bolus injected) and (d) a protein kinase inhibitor (staurosporine, 800 nM infused via the sinus node artery at 0.6 ml min-1 for 15 min). 2. Losartan and staurosporine by themselves had no effect on basal systemic arterial pressure and heart rate, whereas prazosin and nifedipine caused significant diminutions of both parameters. 3. Angiotensin II induced significant increases in heart rate, the mean augmentations being 29 +/- 2 beats min-1. Losartan, nifedipine and staurosporine significantly decreased the chronotropic effect of angiotensin II, the mean respective diminutions being 65 +/- 8, 40 +/- 9 and 64 +/- 10%, whereas prazosin had no effect. 4. This work has demonstrated that angiotensin II exerts in vivo a significant positive chronotropic effect that is mediated via AT1 receptors located in the region of the sinoatrial node. This effect is independent of the adrenergic system. It is decreased by the inhibition of the production of protein kinases, most probably of protein kinase C, and by the blockade of the voltage-sensitive L-type Ca2+ channels.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
795

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs. 1977 Sep;14(3):163–197. doi: 10.2165/00003495-197714030-00002. [DOI] [PubMed] [Google Scholar]
  2. Chardonnens D., Lang U., Rossier M. F., Capponi A. M., Vallotton M. B. Inhibitory and stimulatory effects of phorbol ester on vasopressin-induced cellular responses in cultured rat aortic smooth muscle cells. J Biol Chem. 1990 Jun 25;265(18):10451–10457. [PubMed] [Google Scholar]
  3. Chiu A. T., McCall D. E., Ardecky R. J., Duncia J. V., Nguyen T. T., Timmermans P. B. Angiotensin II receptor subtypes and their selective nonpeptide ligands. 1990-1991 WinterReceptor. 1(1-2):33–40. [PubMed] [Google Scholar]
  4. Doursout M. F., Chelly J. E., Hartley C. J., Szilagyi J., Montastruc J. L., Buckley J. P. Regional blood flows and cardiac function changes induced by angiotensin II in conscious dogs. J Pharmacol Exp Ther. 1988 Aug;246(2):591–596. [PubMed] [Google Scholar]
  5. Dzau V. J. Implications of local angiotensin production in cardiovascular physiology and pharmacology. Am J Cardiol. 1987 Jan 23;59(2):59A–65A. doi: 10.1016/0002-9149(87)90178-0. [DOI] [PubMed] [Google Scholar]
  6. Hewett K. W., Rosen M. R. Developmental changes in the rabbit sinus node action potential and its response to adrenergic agonists. J Pharmacol Exp Ther. 1985 Nov;235(2):308–312. [PubMed] [Google Scholar]
  7. Knape J. T., van Zwieten P. A. Positive chronotropic activity of angiotensin II in the pithed normotensive rat is primarily due to activation of cardiac beta 1-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):185–190. doi: 10.1007/BF00174868. [DOI] [PubMed] [Google Scholar]
  8. Lambert C., Godin D., Fortier P., Nadeau R. Direct effects in vivo of angiotensins I and II on the canine sinus node. Can J Physiol Pharmacol. 1991 Mar;69(3):389–392. doi: 10.1139/y91-059. [DOI] [PubMed] [Google Scholar]
  9. Lambert C., Ribuot C., Robichaud A., Cusson J. R. Negative chronotropic effect of the atrial natriuretic peptide in an anesthetized dog model. Eur J Pharmacol. 1994 Feb 11;252(3):245–252. doi: 10.1016/0014-2999(94)90169-4. [DOI] [PubMed] [Google Scholar]
  10. Lee W. B., Ismay M. J., Lumbers E. R. Mechanisms by which angiotensin II affects the heart rate of the conscious sheep. Circ Res. 1980 Aug;47(2):286–292. doi: 10.1161/01.res.47.2.286. [DOI] [PubMed] [Google Scholar]
  11. Lindpaintner K., Ganten D. The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ Res. 1991 Apr;68(4):905–921. doi: 10.1161/01.res.68.4.905. [DOI] [PubMed] [Google Scholar]
  12. Matsui T., Takuwa Y., Johshita H., Yamashita K., Asano T. Possible role of protein kinase C-dependent smooth muscle contraction in the pathogenesis of chronic cerebral vasospasm. J Cereb Blood Flow Metab. 1991 Jan;11(1):143–149. doi: 10.1038/jcbfm.1991.17. [DOI] [PubMed] [Google Scholar]
  13. Nadeau R. A., James T. N. The behavior of atrio-ventricular nodal rhythm following direct perfusion of the sinus node. Can J Physiol Pharmacol. 1966 Mar;44(2):317–324. doi: 10.1139/y66-036. [DOI] [PubMed] [Google Scholar]
  14. Rogers T. B., Gaa S. T., Allen I. S. Identification and characterization of functional angiotensin II receptors on cultured heart myocytes. J Pharmacol Exp Ther. 1986 Feb;236(2):438–444. [PubMed] [Google Scholar]
  15. Saavedra J. M., Viswanathan M., Shigematsu K. Localization of angiotensin AT1 receptors in the rat heart conduction system. Eur J Pharmacol. 1993 Apr 28;235(2-3):301–303. doi: 10.1016/0014-2999(93)90150-g. [DOI] [PubMed] [Google Scholar]
  16. Saito K., Gutkind J. S., Saavedra J. M. Angiotensin II binding sites in the conduction system of rat hearts. Am J Physiol. 1987 Dec;253(6 Pt 2):H1618–H1622. doi: 10.1152/ajpheart.1987.253.6.H1618. [DOI] [PubMed] [Google Scholar]
  17. Schwartz K. M., Urthaler F., James T. N. The direct negative chronotropic action of prazosin on the canine sinus node. J Pharmacol Exp Ther. 1982 Jun;221(3):801–805. [PubMed] [Google Scholar]
  18. Sechi L. A., Griffin C. A., Grady E. F., Kalinyak J. E., Schambelan M. Characterization of angiotensin II receptor subtypes in rat heart. Circ Res. 1992 Dec;71(6):1482–1489. doi: 10.1161/01.res.71.6.1482. [DOI] [PubMed] [Google Scholar]
  19. Stanaszek W. F., Kellerman D., Brogden R. N., Romankiewicz J. A. Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs. 1983 Apr;25(4):339–384. doi: 10.2165/00003495-198325040-00002. [DOI] [PubMed] [Google Scholar]
  20. Takenaka T., Forster H., Epstein M. Protein kinase C and calcium channel activation as determinants of renal vasoconstriction by angiotensin II and endothelin. Circ Res. 1993 Oct;73(4):743–750. doi: 10.1161/01.res.73.4.743. [DOI] [PubMed] [Google Scholar]
  21. Talajic M., Nattel S. Frequency-dependent effects of calcium antagonists on atrioventricular conduction and refractoriness: demonstration and characterization in anesthetized dogs. Circulation. 1986 Nov;74(5):1156–1167. doi: 10.1161/01.cir.74.5.1156. [DOI] [PubMed] [Google Scholar]
  22. Tamaoki T., Nomoto H., Takahashi I., Kato Y., Morimoto M., Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun. 1986 Mar 13;135(2):397–402. doi: 10.1016/0006-291x(86)90008-2. [DOI] [PubMed] [Google Scholar]
  23. Tamaoki T. Use and specificity of staurosporine, UCN-01, and calphostin C as protein kinase inhibitors. Methods Enzymol. 1991;201:340–347. doi: 10.1016/0076-6879(91)01030-6. [DOI] [PubMed] [Google Scholar]
  24. Terzic A., Pucéat M., Vassort G., Vogel S. M. Cardiac alpha 1-adrenoceptors: an overview. Pharmacol Rev. 1993 Jun;45(2):147–175. [PubMed] [Google Scholar]
  25. Timmermans P. B., Wong P. C., Chiu A. T., Herblin W. F., Benfield P., Carini D. J., Lee R. J., Wexler R. R., Saye J. A., Smith R. D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993 Jun;45(2):205–251. [PubMed] [Google Scholar]
  26. Timmermans P. B., Wong P. C., Chiu A. T., Herblin W. F. Nonpeptide angiotensin II receptor antagonists. Trends Pharmacol Sci. 1991 Feb;12(2):55–62. doi: 10.1016/0165-6147(91)90498-h. [DOI] [PubMed] [Google Scholar]
  27. Xu Y., Sandirasegarane L., Gopalakrishnan V. Protein kinase C inhibitors enhance endothelin-1 and attenuate vasopressin and angiotensin II evoked [Ca2+]i elevation in the rat cardiomyocyte. Br J Pharmacol. 1993 Jan;108(1):6–8. doi: 10.1111/j.1476-5381.1993.tb13430.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES